Page 21 - Amy Wolf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OAN parent company ordered to pay MSNBC, Rachel Maddow $250,000 after losing defamation lawsuit Hannah Yasharoff, USA TODAY Replay Video UP NEXT A judge ordered the parent company for right-wing cable network One America News Network to pay MSNBC and host Rachel Maddow nearly $250,000 in legal fees after a failed defamation lawsuit. Herring Networks, which owns OAN, sued MSNBC for $10 million in September 2019 following a segment on Maddow's show, in which she said OAN "really literally is paid Russian propaganda." The network called the claims "malicious" and "utterly an...

Plan to Live: 3 special women enrich my life I recently had contact with three lovely women who have played important parts in my life. First, there was Gwen. She and husband Fred moved from Richmond to get away from the violence. They were my next-door neighbors for years when I lived in Suisun City. We helped each other when we could. Gwen was at my house probably more than her own during the final two years of my sweet wife Zella’s fight with Alzheimer’s. Gwen was a former nurse and was a great help to me and Zella.

5 classic D.C. Christmas traditions that you can watch from home Fritz Hahn For many people in the Washington area, seeing “A Christmas Carol” at Ford’s Theatre or Step Afrika’s “Magical Musical Holiday Step Show” at the Atlas Performing Arts Center is as much a part of the holidays as gathering around a table with family. And while the coronavirus has pressed pause on these traditions, you can still enjoy the festive performances streaming on your tablet — or on an old-fashioned radio. “A Christmas Carol” Two Ways There are two ways to experience Charle...

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the pe...

Posted December 15th, 2020 for Novartis In Phase III KESTREL study , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit...